Fluad Quadrivalent (inactivated quadrivalent influenza vaccine) / CSL Behring - LARVOL DELTA

Early lymph node T follicular helper cell signalling hub drives influenza vaccine response in an ancestrally diverse cohort. (PubMed, EBioMedicine) - "Early CD4+ Tfh coordination in draining lymphoid tissue underpins robust responses to adjuvanted influenza vaccine that transcend ancestral inter-individual variation in young adults, with implications for vaccine design in ancestrally-diverse populations."

Journal • Infectious Disease • Influenza • Respiratory Diseases • CD4

Brand-specific influenza vaccine effectiveness in three Nordic countries during the 2024-2025 season: a target trial emulation study based on registry data. (PubMed, Lancet Reg Health Eur) - "Brand-specific VE was 63.4% (38.1-88.7) for Efluelda Tetra (split virion-high dose), 48.2% (40.8-55.6) for Fluad Tetra (subunit standard-dose adjuvanted), 43.6% (23.7-63.6) for Vaxigrip Tetra (split virion standard-dose), and 30.6% (-7.8 to 69.1) for Influvac Tetra (subunit standard-dose)...Annual monitoring using Nordic registries is crucial for informing evidence-based vaccination strategies and regulatory decisions. European Medicines Agency."

Journal • Infectious Disease • Influenza • Respiratory Diseases

Influenza Vaccination Appropriateness: Insights from the Local Health Unit of Catania During the 2023/2024 and 2024/2025 Seasons. (PubMed, Vaccines (Basel)) - "All other groups maintained high adherence (≥99%), except for 6.2% of children aged 6 months-2 years who inappropriately received LAIV. Despite dramatically improved vaccination appropriateness in the elderly, a persistent and critical safety issue--inappropriate administration LAIV use in 6.2% of young children-highlights the need for targeted interventions to ensure complete patient safety."

Journal • Infectious Disease • Influenza • Respiratory Diseases

Health Technology Assessment del vaccino antinfluenzale quadrivalente adiuvato Fluad Tetra®: update. (PubMed, J Prev Med Hyg) - No abstract available

Journal • Infectious Disease • Respiratory Diseases

Comparable Effectiveness of MF59®-Adjuvanted and High-Dose Quadrivalent Inactivated Influenza Vaccines for Prevention of Test-Confirmed Influenza During the 2022-2023 Influenza Season. (PubMed, Int J Infect Dis) - "Similar to previous studies, aQIV and HD-QIV provided comparable protection against test-confirmed influenza in any setting, including ED/inpatient, aligning with ACIP and other recommendations for adults ≥65 years."

Journal • Infectious Disease • Influenza • Respiratory Diseases

Muscle macrophage regenerative response after squalene-adjuvanted influenza vaccination drives Th2-skewed response and is reduced with age (IMMUNOLOGY 2025) - "The yBMDMs infiltrated the muscle, internalized the vaccine, and drained to the lymph nodes, rescuing the Th2 response in the lungs. Our findings highlight the role of macrophages in vaccine response and underscore the importance of studying muscle regeneration and factors affecting it like age when developing vaccines.Keywords: Animals Rodent; Cells Monocytes/Macrophages Th1/Th2 Cells; Infections Viral; Processes Antigen Presentation/Processing"

Clinical • Infectious Disease • Influenza • Respiratory Diseases • CD8 • CX3CR1

Cost-Effectiveness of Adjuvanted Influenza Vaccine Compared with Standard and High-Dose Influenza Vaccines for Persons Aged ≥50 Years in Spain. (PubMed, Vaccines (Basel)) - "In the model, aQIV dominated QIVe and HD-QIV, demonstrating that aQIV use would be cost-saving for persons aged ≥50 years who are at high risk of influenza complications."

HEOR • Journal • Infectious Disease • Influenza • Respiratory Diseases

Does Repeat Influenza Vaccination Constrain Influenza Immune Responses and Protection (clinicaltrials.gov) - P=N/A | N=1500 | Active, not recruiting | Sponsor: University of Melbourne | Recruiting ➔ Active, not recruiting | Trial completion date: Nov 2023 ➔ Jun 2025 | Trial primary completion date: Nov 2023 ➔ Jun 2025

Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older. (PubMed, Vaccine) - P2 | "These data support further investigation of additional formulations of aQIVc in adults aged ≥50 years. Clinical trial registry:NCT04576702."

Journal • P2 data • Infectious Disease • Influenza • Respiratory Diseases

Immunogenicity and safety of the MF59-adjuvanted seasonal influenza vaccine in non-elderly adults: A systematic review and meta-analysis. (PubMed, PLoS One) - "In non-elderly adults, aTIV/aQIV is safe and generally more immunogenic than non-adjuvanted standard-dose vaccines."

Journal • Retrospective data • Infectious Disease • Influenza • Respiratory Diseases

Relative Vaccine Effectiveness of Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aQIV) vs High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-QIV) Against Test-Confirmed Influenza During the 2022-2023 Influenza Season (ISIRV-OPTIONS XII 2024) - No abstract available

Clinical • Infectious Disease • Influenza • Respiratory Diseases

Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial. (PubMed, Clin Infect Dis) - P3 | "Adjuvanted FLU-aQIV and RSVPreF3 OA had acceptable reactogenicity/safety profiles when co-administered in ≥65-year-olds, without clinically relevant interference with the immune responses to either vaccine."

Journal • P3 data • Infectious Disease • Influenza • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age (clinicaltrials.gov) - P3 | N=35800 | Recruiting | Sponsor: Seqirus | Active, not recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Influenza • Respiratory Diseases

Cost-Effectiveness of Adjuvanted Quadrivalent Influenza Vaccine for Adults over 65 in France. (PubMed, Vaccines (Basel)) - "This study highlights the cost-effectiveness of aQIV versus SD-QIV and HD-QIV, preventing influenza cases, hospitalizations, and deaths."

Cost effectiveness • HEOR • Journal • Infectious Disease • Influenza • Respiratory Diseases

EDUCATE: Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP (clinicaltrials.gov) - P3 | N=192 | Active, not recruiting | Sponsor: Centers for Disease Control and Prevention | Trial completion date: Mar 2024 ➔ Mar 2026

Trial completion date • Infectious Disease • Influenza • Respiratory Diseases

Use of Adjuvanted Quadrivalent Influenza Vaccine in Older-Age Adults: A Systematic Review of Economic Evidence. (PubMed, Vaccines (Basel)) - "One paper that reported contrary findings adopted a distinct modelling approach. It is reasonable to conclude that there is a broad consensus as to the cost-effectiveness of aQIV in this population group."

Journal • Review • Infectious Disease • Influenza • Respiratory Diseases

Cost-effectiveness of the adjuvanted quadrivalent influenza vaccine for older adults in South Korea. (PubMed, Hum Vaccin Immunother) - "With an ICER of $29,267/QALY, considerably lower than the $34,998/QALY willingness-to-pay threshold, aQIV presents as a cost-effective option. Thus, implementing aQIV with at least 56.1% efficacy is beneficial from both financial and public health perspectives in mitigating seasonal influenza in South Korea."

Cost effectiveness • HEOR • Journal • Infectious Disease • Influenza • Respiratory Diseases

A Study of Modified mRNA Vaccines in Healthy Adults (clinicaltrials.gov) - P1 | N=308 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Trial completion date: Mar 2024 ➔ Feb 2026 | Trial primary completion date: Mar 2024 ➔ Feb 2026

Trial completion date • Trial primary completion date • Cytomegalovirus Infection • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

EDUCATE: Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP (clinicaltrials.gov) - P3 | N=192 | Active, not recruiting | Sponsor: Centers for Disease Control and Prevention | Trial completion date: Nov 2023 ➔ Mar 2024

Trial completion date • Infectious Disease • Influenza • Respiratory Diseases

A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Quadrivalent Influenza Vaccine Compared to a Non-adjuvanted Quadrivalent Influenza Vaccine in Adults ≥65 Years of Age (clinicaltrials.gov) - P3 | N=35800 | Active, not recruiting | Sponsor: Seqirus | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Influenza • Respiratory Diseases

Modelling the population-level benefits and cost-effectiveness of cell-based quadrivalent influenza vaccine for children and adolescents aged 6 months to 17 years in the US. (PubMed, Expert Rev Vaccines) - "Cost savings were estimated at approximately $468 million and $1.366 billion for high and low incidence seasons, respectively. Use of QIVc instead of QIVe in children >6 months of age in the US would reduce the disease burden and be cost-saving from both a payer and societal perspective."

Cost effectiveness • HEOR • Journal • Infectious Disease • Influenza • Respiratory Diseases

Time lapses between distribution of influenza vaccines to health authorities and their administration by General Practitioners (GPs) to older adults: a retrospective study over five influenza seasons in Italy. (PubMed, Expert Rev Vaccines) - "An association was observed for each differential dose/week between distributed and administered vaccines and all-cause hospitalizations with a 10% increase in 2017-2018, 54% in 2018-2019, and 12% in 2020-2021 season. These findings highlight the importance of minimizing the time lapse between vaccine distribution and administration to mitigate the impact of influenza and address factors that contribute to vaccination barriers."

Journal • Retrospective data • Infectious Disease • Influenza • Respiratory Diseases

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above (clinicaltrials.gov) - P3 | N=1045 | Completed | Sponsor: GlaxoSmithKline | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Influenza • Respiratory Diseases • Respiratory Syncytial Virus Infections

Cost-effectiveness for high dose quadrivalent versus the adjuvanted quadrivalent influenza vaccine in the Italian older adult population. (PubMed, Front Public Health) - "The robustness of the results was confirmed in one-way and probabilistic sensitivity analyses. Switching to HD-QIV from aQIV for the older adult in Italy would improve health-related outcomes, and would be cost-effective or cost saving."

Cost effectiveness • HEOR • Journal • Infectious Disease • Influenza • Respiratory Diseases

A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Quadrivalent Influenza Vaccine Compared to a Non-adjuvanted Quadrivalent Influenza Vaccine in Adults ≥65 Years of Age (clinicaltrials.gov) - P3 | N=35800 | Recruiting | Sponsor: Seqirus

Trial completion date • Infectious Disease • Influenza • Respiratory Diseases